Nevro CORP

Nevro Corp. is now a wholly-owned subsidiary of Globus Medical after the completion of a merger on April 3, 2025, with Nevro shareholders receiving $5.85 per share.

Nevro Corp. stockholders approved the merger agreement with Globus Medical at a special meeting held on April 2, 2025.

Nevro Corp. announced its fourth-quarter and full-year 2024 financial results, highlighting a decrease in revenue but exceeding adjusted EBITDA expectations, while also noting the pending acquisition by Globus Medical.

Globus Medical will acquire Nevro in an all-cash transaction for $5.85 per share, aiming to expand treatment options for patients and create a combined medical technology leader.

Nevro Corp. reports preliminary Q4 and full-year 2024 revenue, exceeding prior guidance for the year but showing a year-over-year decrease.

Nevro Corp. reported a decrease in third-quarter revenue but raised its full-year adjusted EBITDA guidance, highlighting the impact of restructuring efforts and new product launches.

Nevro Corp. experienced a decrease in revenue during the third quarter of 2024, alongside ongoing restructuring initiatives aimed at improving profitability.

Nevro Corp. experienced a slight revenue decrease in Q2 2024, alongside increased operating expenses and restructuring charges, impacting overall profitability.

Nevro Corp. announced its first quarter 2024 financial results, showing a 6% increase in revenue compared to the same period last year, driven by growth in the U.S. market and the inclusion of SI Joint product revenue.

Nevro Corp.'s 2024 10-K filing reveals a pending merger with Globus Medical, alongside financial results impacted by market headwinds and strategic shifts.

Nevro Corp.'s 10-K filing highlights its focus on expanding its chronic pain solutions, including its HFX spinal cord stimulation platform and recent acquisition of Vyrsa Technologies.

D. Keith Grossman, a director of Nevro Corp., reported the disposition of 228,552 shares of common stock due to the merger with Globus Medical, Inc., where each share was converted into the right to receive $5.85 in cash.

Director Sridhar Kosaraju reports the disposal of Nevro Corp. shares due to the merger with Globus Medical, where each share was converted into $5.85 in cash.

Christofer Christoforou, SVP and Chief Operating Officer of Nevro Corp., disposed of 363,765 shares of common stock as a result of the merger with Globus Medical, Inc.

SVP, Chief Operating Officer of Nevro Corp., Christofer Christoforou, reports acquisition of performance stock units and disposition of shares to cover tax obligations.

SVP Kashif Rashid reports acquisition of shares through PSU vesting and disposition of shares to cover tax obligations.

Roderick H. MacLeod, SVP and CFO of Nevro Corp., reports acquisition and disposal of common stock and vesting of Performance Stock Units.

Nevro Corp. and Globus Medical have announced a definitive agreement for Globus Medical to acquire Nevro, creating a combined medical technology leader with approximately $3 billion in annual sales.

Globus Medical will acquire Nevro in an all-cash transaction for $5.85 per share, aiming to expand treatment options for patients and create a combined medical technology leader.

Nevro Corp. will hold its annual stockholder meeting virtually on May 23, 2024, to vote on director elections, auditor ratification, and executive compensation.

Nevro Corp. will hold its annual stockholders meeting online on May 23, 2024, to vote on director elections, auditor ratification, and executive compensation.

Beryl Capital Management and its affiliates have reported divesting their entire beneficial ownership in Nevro Corp, now holding 0% of the common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a 0.0% beneficial ownership stake in Nevro Corp. common stock as of June 30, 2025.